Trials / NCT01399515
Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Seoul National University Hospital
- Treatment
- Valproic Acid
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Retinal Diseases, Eye Diseases, Eye Disease, Hereditary, Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 200 participants
- Started
- 2011-03
- Main results expected
- 2013-08
- Results posted
- Not yet
- Record last updated
- 2016-04-14
What the study is testing
The purpose of this study is to evaluate the efficacy and safety of oral valproic acid to slow the progression of visual function and/or to improve the visual function in patients with retinitis pigmentosa (RP).
Enrolled subjects in valproic acid group will be treated with oral valproic acid 500mg daily for 48 weeks. Visual function and safety will be assess before and after treatment (48 weeks) between valproic acid and control groups.
Where it runs
South Korea (1)
- Department of Ophthalmology, Seoul National University Hospital, Seoul